Show
Sort by
-
Long-term follow-up, up to 7 years, in the RESONATE-2 study of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL)
(2021) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. In Clinical Lymphoma Myeloma & Leukemia 21(Supplement 1). p.S316-S316 -
Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
-
- Journal Article
- A1
- open access
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia : results from the pivotal phase III study COMPLEMENT1
-
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil : final analysis of the Complement 1 phase 3 trial
-
Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged >= 65 year of age : results with 5 years of follow-up for the RESONATE-2 study
-
- Journal Article
- A1
- open access
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL : 5 years of follow-up from the phase 3 RESONATE-2 study
-
- Journal Article
- A1
- open access
Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia : final analysis of the PROLONG study
-
Five-year follow-up after ibrutinib therapy for first-line treatment of chronic lymphocytic leukemia
-
Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL) : final analysis of the phase 3 COMPLEMENT 1 trial.
-
- Journal Article
- A1
- open access
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : extended phase 3 results from RESONATE-2
-
Role of ofatumumab (OFA) maintenance treatment in relapsed chronic lymphocytic leukemia (CLL): Final analysis of PROLONG study.
-
Phase 3 study of ibrutinib as first-line treatment in older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) : a 4-year follow-up from the RESONATE-2 study
-
Updated efficacy and safety from the phase 3 resonate-2 study : ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia
-
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL
-
Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL
-
International, randomized phase 3 study results : Ibrutinib versus Chlorambucil in patients 65 years and older with treatment-naive CLL (RESONATE-2 (TM))
-
Improvement in quality of life and well-being in older patients with treatment-naive (TN) CLL : results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (resonate-2™)
-
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
-
Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive (TN) CLL/SLL (RESONATE-2 (TM))
-
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
-
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
-
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
-
Health related quality of life and patient reported outcomes in patients receiving ofatumumab maintenance versus observation in the Prolong trial
-
Telomere length and POT1 mutations in CLL: incidence, associations and clinical impact in the Complement 1 trial
-
Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naive CLL/SLL (RESONATE-2 (TM))
-
SF3B1 mutations and outcome in CLL patients treated with chlorambucil (CHL) or ofatumumab-CHL (O plus CHL): results from the phase III study complement 1 (OMB110911)
-
Gene mutations and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-Chl (O-Chl): results from the phase III study COMPLEMENT1 (OMB110911)
-
Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911)
-
NOTCH1 mutation and treatment outcome in CLL patients treated with chlorambucil (Chl) or ofatumumab-chi (O-Chl): results from the phase III study complement 1 (OMB110911)